Last edition
News about "Roche"
Oxford BioTherapeutics and Roche to Research on Novel Targets for Antibody-Based Therapeutics
OBT’s recently launched enhanced proprietary OGAP®-Verify discovery platform enables greater sensitivity and thereby the selection of targets with improved attributes for drug development.
Roche | 25/03/2025 | By Aishwarya
Zealand Pharma and Roche to Develop and Commercialize Petrelintide
The two companies will co-develop and co-commercialize petrelintide and combination products with petrelintide, including a fixed-dose combination product of petrelintide and CT-388, Roche’s lead incretin asset and potential best-in-class GLP-1/GIP receptor dual agonist.
Roche | 15/03/2025 | By Aishwarya
Innovent Signs Exclusive Global License Deal with Roche for Novel DLL3 Antibody Drug Conjugate
IBI3009 targets DLL3, an antigen with low expression in normal tissues but significantly overexpressed in certain cancers, particularly small-cell lung cancer and other neuroendocrine tumors.
Roche | 02/01/2025 | By Aishwarya
Roche Announces Acquisition of Poseida Therapeutics
The proposed acquisition will establish a new core capability for Roche in allogeneic cell therapy, with lead opportunities focused on CAR-T programs covered by the existing strategic collaboration between Poseida and Roche in hematologic malignancies.
Roche | 03/12/2024 | By Aishwarya
Flare Therapeutics Partners with Roche Accelerate Drug Discovery in Oncology
This partnership will leverage Flare Therapeutics' proteomic and mass spectrometry platform and expertise, powered by its proprietary library of electrophilic compounds, to discover novel small molecule drugs aimed at previously undrugged transcription factor targets in oncology.
Roche | 14/11/2024 | By Aishwarya | 143
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza with ENHANZE
Tecentriq Hybreza can be injected subcutaneously in approximately 7 minutes compared to 30-60 minutes for standard intravenous (IV) infusion of Tecentriq (atezolizumab).
Roche | 13/09/2024 | By Aishwarya | 152
Roche Inaugurates Pharma Research and Development Center in Basel
Roche has launched its new Pharma Research and Early Development (pRED) Center at its global headquarters in Basel, Switzerland.
Roche | 11/09/2024 | By Aishwarya | 178
Ascidian Partners with Roche for Development of RNA Exon Editing Therapeutics
Ascidian Therapeutics has signed a research collaboration and licensing agreement with Roche for the discovery and development of RNA exon editing therapeutics targeting neurological diseases.
Roche | 19/06/2024 | By Aishwarya | 130
ALZpath Signs Licensing Deal with Roche for Use of pTau217 Antibody in Blood Test
ALZpath, Inc. has signed a strategic license agreement with Roche for the use of the ALZpath pTau217 antibody to develop and commercialize an Alzheimer's disease diagnostic blood test.
Roche | 11/06/2024 | By Aishwarya | 367
Roche announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc
Roche | 28/05/2020 | By Darshana | 439
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy